TRPM4 in Bladder Cancer: Prognostic Gene Risk Model and Drug Sensitivity Data

220 candidate genes were identified from integrated single-cell and transcriptomic analyses of bladder cancer (BLCA). A risk model was constructed using six prognostic marker genes (UNC93B1, FAM193B, POGLUT3, FBN1, MAP1B, RUNX2), and drug sensitivity analysis identified 112 drugs with differential responses. The dataset, authored by Qi Zhao and last updated in April 2026, supports the prognostic value of TRPM4 in BLCA.

Use Cases

• Validate the six-gene prognostic risk model (UNC93B1, FAM193B, POGLUT3, FBN1, MAP1B, RUNX2) based on the described analysis.
• Analyze immune infiltration patterns based on the 12 distinct immune cell types identified, including naive B cells.
• Investigate drug sensitivity correlations based on the 112 drugs showing differential responses, such as WZ3105.
• Explore pathway enrichment disparities, such as the melanoma pathway, based on the gene set enrichment analysis results.

Strengths

• Includes results from integrated single-cell and whole-genome transcriptomic analyses.
• Identifies 220 candidate genes and a six-gene prognostic model with statistical significance (p < 0.05).
• Contains drug sensitivity analysis results for 112 specific drugs.

Limitations

• Column-level documentation is absent; field semantics must be inferred after download.
• Row count is unknown, which may limit suitability assessment.

Provenance

Source

figshare, author Qi Zhao.

Collection Method

Data likely results from computational integration of single-cell and transcriptomic datasets, intersection analysis, and statistical modeling.

Time Range

null

Freshness

Last updated 2026-04-13 05:21:52; freshness should be verified.

Geography

null